• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

匹杉琼用于治疗复发或难治性侵袭性非霍奇金B细胞淋巴瘤的成年患者。

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

作者信息

Volpetti Stefano, Zaja Francesco, Fanin Renato

机构信息

Division of Hematology and Cellular Therapies Unit "Carlo Melzi", Department of Experimental and Clinical Sciences, University Hospital "Santa Maria della Misericordia", Udine, Italy.

出版信息

Onco Targets Ther. 2014 May 29;7:865-72. doi: 10.2147/OTT.S34055. eCollection 2014.

DOI:10.2147/OTT.S34055
PMID:24926199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4049882/
Abstract

Treatment of patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphoma remains an unmet clinical need, and the progressive myocardial toxicity related to cumulative, dose-dependent damage induced by anthracyclines represents a tricky issue in the planning of therapy. Pixantrone is a promising aza-anthracenedione with reduced cardiotoxicity and significant antineoplastic activity, and has been investigated in solid and hematologic tumors in several Phase I, II, and III trials. The aim of this review is to summarize the data reported so far on pixantrone as a salvage therapy in relapsed/refractory non-Hodgkin B-cell lymphoma.

摘要

复发或难治性侵袭性非霍奇金B细胞淋巴瘤患者的治疗仍然是一项未得到满足的临床需求，而蒽环类药物诱导的累积性、剂量依赖性损伤所导致的进行性心肌毒性是治疗方案制定中的一个棘手问题。匹杉琼是一种有前景的氮杂蒽二酮，具有降低的心脏毒性和显著的抗肿瘤活性，已在多项I期、II期和III期试验中针对实体瘤和血液系统肿瘤进行了研究。本综述的目的是总结迄今为止报道的关于匹杉琼作为复发/难治性非霍奇金B细胞淋巴瘤挽救疗法的数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a86/4049882/ff2fec8d1403/ott-7-865Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a86/4049882/ff2fec8d1403/ott-7-865Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a86/4049882/ff2fec8d1403/ott-7-865Fig1.jpg

相似文献

1
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.匹杉琼用于治疗复发或难治性侵袭性非霍奇金B细胞淋巴瘤的成年患者。
Onco Targets Ther. 2014 May 29;7:865-72. doi: 10.2147/OTT.S34055. eCollection 2014.
2
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.马来酸吡柔比星对比其他化疗药物作为复发或难治性侵袭性非霍奇金淋巴瘤患者的单药挽救治疗：一项 3 期、多中心、开放标签、随机试验。
Lancet Oncol. 2012 Jul;13(7):696-706. doi: 10.1016/S1470-2045(12)70212-7. Epub 2012 May 30.
3
Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.用于治疗侵袭性非霍奇金淋巴瘤的比卡鲁胺。
Expert Opin Pharmacother. 2010 Aug;11(11):1915-23. doi: 10.1517/14656566.2010.494180.
4
Pixantrone maleate for non-Hodgkin's lymphoma.马来酸匹杉琼用于治疗非霍奇金淋巴瘤。
Drugs Today (Barc). 2009 Nov;45(11):797-805. doi: 10.1358/dot.2009.45.11.1438459.
5
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.皮沙酮治疗复发性或难治性侵袭性非霍奇金 B 细胞淋巴瘤的疗效和安全性。
Eur J Haematol. 2020 May;104(5):499-508. doi: 10.1111/ejh.13392. Epub 2020 Feb 11.
6
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma.关于匹杉琼治疗非霍奇金B细胞淋巴瘤的当前观点
Ther Clin Risk Manag. 2021 Mar 2;17:183-192. doi: 10.2147/TCRM.S269324. eCollection 2021.
7
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.欧洲药品管理局审查匹钽龙治疗成人复发性或难治性侵袭性非霍奇金 B 细胞淋巴瘤：人用药品委员会对科学评估的总结。
Oncologist. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24.
8
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.治疗非霍奇金淋巴瘤的比星替康的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1441-8. doi: 10.1517/17425255.2011.618834. Epub 2011 Sep 12.
9
An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma.评价吡柔比星治疗非霍奇金淋巴瘤。
Expert Opin Pharmacother. 2018 Nov;19(16):1829-1834. doi: 10.1080/14656566.2018.1528232. Epub 2018 Oct 1.
10
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.比卡鲁胺：复发或难治侵袭性非霍奇金淋巴瘤的研究进展。
Drugs. 2016 Oct;76(16):1579-1586. doi: 10.1007/s40265-016-0650-8.

引用本文的文献

1
Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma.关于匹杉琼治疗非霍奇金B细胞淋巴瘤的当前观点
Ther Clin Risk Manag. 2021 Mar 2;17:183-192. doi: 10.2147/TCRM.S269324. eCollection 2021.
2
Friend or Foe: Xenobiotic Activation of Nrf2 in Disease Control and Cardioprotection.敌友难辨：外源性物质对Nrf2的激活在疾病控制和心脏保护中的作用
Pharm Res. 2021 Feb;38(2):213-241. doi: 10.1007/s11095-021-02997-y. Epub 2021 Feb 22.
3
A Survey of Synthetic Routes and Antitumor Activities for Benzo[]quinoxaline-5,10-diones.

本文引用的文献

1
Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.比较基于 pixantrone 的方案（CPOP-R）与基于多柔比星的治疗（CHOP-R）治疗弥漫性大 B 细胞淋巴瘤。
Ann Oncol. 2013 Oct;24(10):2618-2623. doi: 10.1093/annonc/mdt289. Epub 2013 Aug 14.
2
Anthracycline-containing regimens for treatment of follicular lymphoma in adults.含蒽环类药物的方案用于治疗成人滤泡性淋巴瘤。
Cochrane Database Syst Rev. 2013 Jul 7;2013(7):CD008909. doi: 10.1002/14651858.CD008909.pub2.
3
The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.
苯并[ ]喹喔啉-5,10-二酮的合成路线及抗肿瘤活性研究综述。
Molecules. 2020 Dec 14;25(24):5922. doi: 10.3390/molecules25245922.
4
Limited efficacy of pixantrone in refractory diffuse large B-cell lymphoma.匹杉琼在难治性弥漫性大B细胞淋巴瘤中的疗效有限。
Oncol Lett. 2020 Mar;19(3):2028-2034. doi: 10.3892/ol.2020.11288. Epub 2020 Jan 10.
5
Pixantrone beyond monotherapy: a review.联合治疗以外的比卡鲁胺：综述。
Ann Hematol. 2019 Sep;98(9):2025-2033. doi: 10.1007/s00277-019-03749-0. Epub 2019 Jul 17.
6
Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells.匹杉琼，一种有着老问题的新型抗癌药物？一项针对分化和未分化H9c2细胞的体外研究。
Interdiscip Toxicol. 2018 May;11(1):13-21. doi: 10.2478/intox-2018-0002. Epub 2018 Aug 6.
7
Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.在复发或难治性侵袭性非霍奇金淋巴瘤患者中使用比卡鲁胺的长期缓解和缓解：多中心、开放标签、随机 PIX301 试验的事后分析。
Clin Drug Investig. 2018 Jun;38(6):527-533. doi: 10.1007/s40261-018-0635-3.
8
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.比卡鲁胺：复发或难治侵袭性非霍奇金淋巴瘤的研究进展。
Drugs. 2016 Oct;76(16):1579-1586. doi: 10.1007/s40265-016-0650-8.
9
In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.新型嵌合人B淋巴细胞CD20额外环的计算机辅助设计、克隆及异源表达
Tumour Biol. 2016 Sep;37(9):12547-12553. doi: 10.1007/s13277-016-5105-z. Epub 2016 Jun 27.
10
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.匹杉琼单药治疗组织学确诊的复发或难治性侵袭性B细胞非霍奇金淋巴瘤：一项III期试验的事后分析
Br J Haematol. 2016 Sep;174(5):692-9. doi: 10.1111/bjh.14101. Epub 2016 Apr 26.
欧洲药品管理局审查匹钽龙治疗成人复发性或难治性侵袭性非霍奇金 B 细胞淋巴瘤：人用药品委员会对科学评估的总结。
Oncologist. 2013;18(5):625-33. doi: 10.1634/theoncologist.2013-0020. Epub 2013 Apr 24.
4
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.新型蒽二酮类药物 pixantrone 缺乏氧化还原活性，并抑制人心肌中多柔比星醇的形成：解释 pixantrone 在多柔比星治疗患者中具有心脏安全性的见解。
J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.
5
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.马来酸吡柔比星对比其他化疗药物作为复发或难治性侵袭性非霍奇金淋巴瘤患者的单药挽救治疗：一项 3 期、多中心、开放标签、随机试验。
Lancet Oncol. 2012 Jul;13(7):696-706. doi: 10.1016/S1470-2045(12)70212-7. Epub 2012 May 30.
6
Combining immunotherapy and targeted therapies in cancer treatment.将免疫疗法和靶向疗法相结合用于癌症治疗。
Nat Rev Cancer. 2012 Mar 22;12(4):237-51. doi: 10.1038/nrc3237.
7
Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.复发侵袭性非霍奇金淋巴瘤患者中 pixantrone 联合环磷酰胺、长春新碱和泼尼松的 I/II 期研究。
Leuk Lymphoma. 2011 Apr;52(4):620-8. doi: 10.3109/10428194.2010.546016.
8
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
9
New developments in anthracycline-induced cardiotoxicity.蒽环类药物所致心脏毒性的新进展
Curr Med Chem. 2009;16(13):1656-72. doi: 10.2174/092986709788186228.
10
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.利妥昔单抗联合DHAP方案挽救性化疗用于复发非霍奇金淋巴瘤：北中部癌症治疗组的一项II期试验
Leuk Lymphoma. 2008 Jun;49(6):1074-80. doi: 10.1080/10428190801993470.